Google
TLSI Stock Price & Analysis — Trisalus Life Sciences Inc. (Healthcare >> Medical Devices)
TLSI FAQ
What is TLSI's P/E ratio?
Trisalus Life Sciences Inc. (TLSI) currently trades at a P/E ratio of 181.97.
What is TLSI's ROE?
Trisalus Life Sciences Inc. reports a Return on Equity (ROE) of -213.27%.
What is TLSI's dividend yield?
Trisalus Life Sciences Inc. offers a dividend yield of 0.00%.
What is TLSI's Quality Score?
Our AI rates TLSI's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TLSI?
Our AI Timing Score for TLSI is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TLSI belong to?
Trisalus Life Sciences Inc. is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange
TLSI AI Analysis Summary
Our AI summary for TLSI: Trisalus Life Sciences Inc. (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 181.97, ROE of -213.27%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.54
Price
-0.02
(-0.44%)
Day Change
|
|
|---|
TLSI, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.54 |
| PBV / Sector |
21.87 / -101.57
|
| Earning Per Share | -0.44 |
| PE / Sector |
181.97 / 31.23
|
| PEG or PE/Growth / Sector |
-26.22 / 0.40
|
| Average 1M Daily Value |
0.91 M
GREAT
|
| Average 1W Daily Value |
0.59 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:35 |
| Symbol | TLSI |
| Name | TRISALUS LIFE SCIENCES INC. |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 61.42 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 280.06 / 20,104.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 6272 West 91st Avenue, Westminster, CO, United States, 80031
Phone: 888 321 5212
Website: https://trisaluslifesci.com
Employees: 102
Sector: Healthcare >> Medical Devices
Description: TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
